Pfizer, the drug-making giant, claims its $160 billion merger with Irish-based Allergan would benefit prescription drug consumers. But the proposal looks more like an attempt to avoid paying U.S. taxes through a legal maneuver called an inversion.

This sort of dodge, which has been performed by dozens of other corporations including Cecil-based drug manufacturer Mylan, would make Allergan, the smaller of the two firms, the purchaser — a new twist on the usual formula. The surviving company, Pfizer Plc, would be based in Dublin and subject to Ireland’s tax laws. The new Pfizer would pay an effective tax rate of 17 to 18 percent, compared with the 25.5 percent it’s been paying to the United States.

Pfizer is America’s largest drug company, with well-known products such as Advil, Centrum, Lipitor, Preparation H and Viagra.

Although this inversion would be a significant drain on the U.S. Treasury, Pfizer CEO Ian C. Read said that, if it is approved by federal regulators and the two companies’ shareholders, the combined firm will be able to invest $9 billion in research on new drugs and medical treatments, thereby leading to more U.S. jobs.

Advertise with us

The growing use of inversions is another argument for tax reform in Washington. The last overhaul came in 1986 under President Ronald Reagan, but corporate “globalization” has far outpaced U.S. tax policy. President Barack Obama and members of Congress have muttered about the need for a major tax revision, but no one has done anything to make it happen.

Meanwhile, former members of Congress who take jobs in the private sector will use their influence to oppose changing the tax code. One of the banks involved in the Pfizer deal is Moelis & Company, where former House Majority Leader Eric Cantor is a vice chairman.

Regardless of whether federal agencies approve this merger, corporate inversions must stop. Congress has several bills before it that would do the job. What it lacks, unfortunately, is the will.

Meet the Editorial Board.